One year of treatment with inebilizumab eased symptoms and improved daily functioning for people with generalized myasthenia gravis (gMG) positive for antibodies against the acetylcholine receptor (AChR), according to new data from the Phase 3 MINT clinical trial. Amgen, the company developing inebilizumab, will present the new…
News
Dosing has started in the first group of healthy adults participating in a clinical study of S-1117, a candidate treatment Seismic Therapeutic designed to break down harmful self-reactive antibodies in autoimmune diseases like myasthenia gravis (MG). Running at a single site in Australia, the Phase 1 clinical…
More than two years of treatment with Zilbrysq (zilucoplan) continues to be associated with sustained clinical responses in adults with generalized myasthenia gravis (gMG), according to interim analyses of the long-term Phase 3 RAISE-XT extension study. These new findings, consistent with earlier interim trial analyses, were presented…
Repeated cycles of Rystiggo (rozanolixizumab-noli) do not increase the risk of safety problems in people with generalized myasthenia gravis (gMG), according to a new analysis of clinical trial data. “These results showed that treatment with [Rystiggo] in patients with gMG was well tolerated and that the incidence of…
The U.S. Food and Drug Administration (FDA) has approved the expanded use of Soliris (eculizumab) for treating children with generalized myasthenia gravis (gMG), ages 6 and older, who are positive for antibodies against the acetylcholine receptor (AChR). The infusion therapy marketed by Alexion, AstraZeneca Rare Disease was…
Rituximab can safely and effectively control myasthenia gravis (MG) in patients with antibodies against muscle-specific kinase or MuSK, according to a new analysis. “Rituximab has demonstrated effectiveness and safety as a treatment for anti-MuSK MG. It has the potential to help patients with any baseline severity, especially those…
The National Organization for Rare Disorders (NORD) is seeking participants for its survey-based study Living Rare, which aims to better understand the real-world lived experiences of people in the U.S. with rare diseases. Living Rare, the first large-scale study of its kind in the U.S., seeks to capture the…
People with myasthenia gravis (MG) who have more severe disease when they are diagnosed, are older at its onset, or have a thymus tumor are at a higher risk of myasthenic crises, a study from Southwest China indicates. According to the researchers, “the results underscore the critical importance…
Note: This story has been updated March 6, 2025, to correct a quote from Mindy Henderson, MDA vice president of disability outreach and empowerment. The Muscular Dystrophy Association (MDA) is once again hosting its annual gathering, the MDA Clinical & Scientific Conference. The 2025 event will take place…
Tacrolimus, an immunosuppressant sometimes used off-label to treat adults with myasthenia gravis (MG), eased symptoms of the disease in about four in every five children with juvenile MG, with few side effects. That’s according to a meta-analysis of nine studies from China and Japan, which also found tacrolimus…
Recent Posts
- Finding ways to reduce suffering, even while living with chronic pain
- Guest Voice: What living between labels taught me about MG
- MG-specific treatments needed for older patients, researchers say
- Polyautoimmunity brings some uninvited guests to my MG party
- FDA approves inebilizumab, now Uplizna, to treat adults with gMG